No Data
No Data
Paulette (300246.SZ) announced its 2023 annual results, changing profit to loss to 65.1851 million yuan
According to the Zhitong Finance App, Paulette (300246.SZ) released its 2023 annual report. The company's revenue was 1,194 billion yuan, an increase of 0.87% over the previous year. The net loss attributable to shareholders of the listed company was 65.1851 million yuan. Net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss was 81.5033 million yuan, an increase of 1149.80% over the previous year. The basic loss per share was $0.247.
Express News | Paulette: Selected Hemodialysis Medical Consumables by Interprovincial Alliance for Centralized Volume Procurement
Paulette (300246.SZ) has been re-certified as a high-tech enterprise
Gelonghui, March 5 | Paulette (300246.SZ) announced that the company recently received the “High-tech Enterprise Certificate” jointly issued by the Guangdong Provincial Department of Science and Technology, the Guangdong Provincial Department of Finance, and the Guangdong Provincial Taxation Bureau of the State Administration of Taxation. The certificate number is GR202344006246. The issuance period is December 28, 2023, and is valid for three years.
Paulette (300246.SZ): Proposed internal transfer of subsidiary shares
Gelonghui, March 4, 丨 Paulette (300246.SZ) announced that the company held the 13th meeting of the 8th board of directors on March 4, 2024 to review and pass the “Proposal on Internal Transfer of Subsidiary Shares”. The board of directors agreed that in order to further optimize the company's management structure, improve business management and operation efficiency, and reduce management costs, the company plans to integrate subsidiaries related to the blood purification consumables business in Tianjin to develop medical devices owned by the wholly-owned subsidiary Tianjin Baolite Technology Co., Ltd. (hereinafter referred to as “Tianjin Medical Baolite”) Co., Ltd. (hereinafter referred to as “Day”
Paulette (300246.SZ) plans to increase Tianjin Baolite's capital by 8.657 million yuan through debt-for-equity swaps
Paulette (300246.SZ) announced that the company plans to use debt-for-equity swaps to Tianjin Baolite Medical Technology Co., Ltd...
Paulette (300246.SZ): A total cost of 6.9097 million yuan to buy back 1,01.05 million shares
Glonghui, March 4, 丨 Paulette (300246.SZ) announced that as of February 29, 2024, the total number of shares repurchased by the company through centralized bidding transactions through the stock repurchase special securities account was 1,010.5 million shares, accounting for 0.3784% of the company's total share capital; the highest transaction price of the repurchase was RMB 7.02 yuan/share, the minimum transaction price was RMB 6.76 yuan/share, and the total transaction amount was RMB 690.097 million (excluding transaction fees such as stamp duty and transaction fees).
No Data